Biohaven Ltd Quick Ratio (BHVN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Biohaven Ltd   (NYSE: BHVN)

Biohaven Ltd 's Quick Ratio

BHVN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 2.57 below Biohaven Ltd average.

Within Major Pharmaceutical Preparations industry 196 other companies have achieved higher Quick Ratio than Biohaven Ltd in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 494 to 883.

Explain Quick Ratio?
How much Cash & cash equivalents BHVN´s has?
What are BHVN´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BHVN/financial-strength
https://api.csimarket.com/api/v1/companies/BHVN/fundamentals
https://api.csimarket.com/api/v1/companies/BHVN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
BHVN Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -44.47 %
Y / Y Cash & cash equivalent Change -38.08 %
Quick Ratio MRQ 2.57
BHVN's Total Ranking # 883
Seq. Current Liabilities Change 0.17 %
Seq. Cash & cash equivalent Change -39.85 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 197
Healthcare Sector # 331
Overall Market # 883


Quick Ratio Statistics
High Average Low
17.05 4.95 0.68
(Jun 30 2018)   (Dec 31 2021)




Financial Statements
Biohaven Ltd 's Current Liabilities $ 63 Millions Visit BHVN's Balance sheet
Biohaven Ltd 's Cash & cash equivalent $ 161 Millions Visit BHVN's Balance sheet
Source of BHVN's Sales Visit BHVN's Sales by Geography


Cumulative Biohaven Ltd 's Quick Ratio

BHVN's Quick Ratio for the trailling 12 Months

BHVN Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -47.19 %
Y / Y Cash & cash equivalent TTM Growth -25.65 %
Quick Ratio TTM 3.73
Total Ranking TTM # 3750
Seq. Current Liabilities TTM Growth -14.62 %
Seq. Cash & cash equivalent TTM Growth -8.29 %


On the trailing twelve months basis Current Liabilities decreased faster than Biohaven Ltd 's average Cash & cash equivalent, this led to increase in in Biohaven Ltd 's Quick Ratio to 3.73, Quick Ratio remained below BHVN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 429 other companies have achieved higher Quick Ratio than Biohaven Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3673 to 3750.

Explain Quick Ratio?
How much Cash & cash equivalents BHVN´s has?
What are BHVN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 430
Healthcare Sector # 874
Within the Market # 3750


trailing twelve months Quick Ratio Statistics
High Average Low
12.17 3.8 0.35
(Mar 31 2019)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Lb Pharmaceuticals Inc  7.03 $ 215.075  Millions$ 30.573  Millions
Zentalis Pharmaceuticals Inc   7.03 $ 228.893  Millions$ 32.539  Millions
Quoin Pharmaceuticals Ltd   6.95 $ 33.184  Millions$ 4.776  Millions
Bullfrog Ai Holdings Inc   6.94 $ 4.990  Millions$ 0.719  Millions
Vera Therapeutics Inc   6.89 $ 384.042  Millions$ 55.775  Millions
Nuvation Bio Inc   6.73 $ 663.370  Millions$ 98.559  Millions
Anaptysbio Inc   6.71 $ 230.319  Millions$ 34.318  Millions
Coya Therapeutics Inc   6.64 $ 35.802  Millions$ 5.395  Millions
Capricor Therapeutics inc   6.61 $ 197.581  Millions$ 29.895  Millions
Arcturus Therapeutics Holdings Inc   6.52 $ 184.817  Millions$ 28.345  Millions
Moonlake Immunotherapeutics  6.50 $ 379.704  Millions$ 58.430  Millions
Kiora Pharmaceuticals Inc   6.47 $ 16.287  Millions$ 2.519  Millions
Camp4 Therapeutics Corporation  6.27 $ 124.522  Millions$ 19.865  Millions
Context Therapeutics Inc   6.26 $ 34.411  Millions$ 5.501  Millions
Sagimet Biosciences inc   6.22 $ 236.397  Millions$ 37.985  Millions
Bridgebio Oncology Therapeutics Inc   6.18 $ 315.331  Millions$ 51.026  Millions
Reviva Pharmaceuticals Holdings Inc   6.14 $ 33.647  Millions$ 5.478  Millions
Cartesian Therapeutics Inc   6.12 $ 122.975  Millions$ 20.088  Millions
Olema Pharmaceuticals Inc   5.98 $ 413.771  Millions$ 69.233  Millions
Summit Therapeutics Inc   5.71 $ 629.899  Millions$ 110.226  Millions
Nurix Therapeutics Inc   5.51 $ 720.458  Millions$ 130.742  Millions
United Therapeutics Corporation  5.51 $ 3,439.800  Millions$ 624.300  Millions
Immuneering Corporation  5.45 $ 58.776  Millions$ 10.791  Millions
Rocket Pharmaceuticals Inc   5.22 $ 279.470  Millions$ 53.508  Millions
Aquestive Therapeutics Inc   5.22 $ 90.349  Millions$ 17.299  Millions
Sionna Therapeutics Inc   5.11 $ 83.878  Millions$ 16.420  Millions
Gain Therapeutics inc  4.94 $ 11.698  Millions$ 2.369  Millions
Rani Therapeutics Holdings Inc   4.91 $ 45.288  Millions$ 9.223  Millions
Abeona Therapeutics Inc   4.87 $ 134.941  Millions$ 27.707  Millions
Hoth Therapeutics Inc   4.87 $ 6.016  Millions$ 1.237  Millions

Date modified: 2026-10-30T14:47:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.